Biomarkers of gastric atrophy at stomach cancer

Background. Atrophic gastritis (AG), being the basic premalignant condition for the stomach cancer (SC), is commonly diagnosed and screened for by noninvasive biomarkers (pepsinogens, gastrin-17), however the data on those biomarkers at SC is inconsistent. Aim of investigation. To evaluate the marke...

Full description

Saved in:
Bibliographic Details
Main Authors: A. V. Belkovets, S. A. Kurilovich., Yu. I. Ragino, L. V. Scherbakova, O. B. Cheremisina, N. V. Cherdyntseva, N. A. Andryushina, M. I. Voyevoda
Format: Article
Language:Russian
Published: Gastro LLC 2018-08-01
Series:Российский журнал гастроэнтерологии, гепатологии, колопроктологии
Subjects:
Online Access:https://www.gastro-j.ru/jour/article/view/226
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823860288051478528
author A. V. Belkovets
S. A. Kurilovich.
Yu. I. Ragino
L. V. Scherbakova
O. B. Cheremisina
N. V. Cherdyntseva
N. A. Andryushina
M. I. Voyevoda
author_facet A. V. Belkovets
S. A. Kurilovich.
Yu. I. Ragino
L. V. Scherbakova
O. B. Cheremisina
N. V. Cherdyntseva
N. A. Andryushina
M. I. Voyevoda
author_sort A. V. Belkovets
collection DOAJ
description Background. Atrophic gastritis (AG), being the basic premalignant condition for the stomach cancer (SC), is commonly diagnosed and screened for by noninvasive biomarkers (pepsinogens, gastrin-17), however the data on those biomarkers at SC is inconsistent. Aim of investigation. To evaluate the markers of stomach atrophy along with risk factors of SC of different localization, histological type and stage in the «case series» study. Material and methods. Original investigation was designed as «case series», that included 85 patients with SC (48 m and 37 f, mean age 61.2±13,6 years) who were consistently referred to two medical institutions. All patients underwent interviewing the questionnaire concerning smoking and alcohol consumption, presence of gastroenterological symptoms and family history. Blood serum samples were analyzed using ELISA test kits «GastroPanel» («Biohit Plc», Finland). Manufacturer recommended threshold levels were used at diagnostics of AG. Results. The diagnosis of SC of the III to IV stage was established in 67.9% of patients. The most common location of the neoplasm was the stomach body (63,5%). Helicobacter pylori (H. pylori) infection was revealed by serological method in 74.1% of cases, of which in 15.1% the attempt of eradication treatment was carried out. In 90.6% of patients the adenocarcinoma of different differentiation grade was diagnosed, low degree of differentiation was the most common (57.6%). Signet-ring cell carcinoma was diagnosed in 7.1% of patients, undifferentiated tumor - in 2.4%. Pepsinogen-I (PGI) level under 50 mcg/l was found in 43.2% of patients, indicating different degrees of fundic atrophy. Significantly lower PGI scores were detected in SC patients with histologically verified atrophy. No significant differences in biomarker levels according to tumor location, histological type of SC and tumor stage were found. Conclusions. The «case series» study demonstrated high rate of late SC diagnostics with predominance of corpus location and the most malignant types. H. pylori infection was diagnosed in serologically in the most of patients, however attempts for eradication therapy was carried out only in 15% of patients. Fundic atrophy was diagnosed by serological tests in over 40% of patients, however no association with location, stage and morphological type of the tumor was established. Blood serum samples were analyzed using ELISA test kits «GastroPanel» («Biohit Plc», Finland). Manufacturer recommended threshold levels were used at diagnostics of AG.
format Article
id doaj-art-6d5c5deac1884c81bb9bd69fbc54ef27
institution Kabale University
issn 1382-4376
2658-6673
language Russian
publishDate 2018-08-01
publisher Gastro LLC
record_format Article
series Российский журнал гастроэнтерологии, гепатологии, колопроктологии
spelling doaj-art-6d5c5deac1884c81bb9bd69fbc54ef272025-02-10T16:14:29ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732018-08-01282243210.22416/1382-4376-2018-28-2-24-32226Biomarkers of gastric atrophy at stomach cancerA. V. Belkovets0S. A. Kurilovich.1Yu. I. Ragino2L. V. Scherbakova3O. B. Cheremisina4N. V. Cherdyntseva5N. A. Andryushina6M. I. Voyevoda7Institute of Cytology and GeneticsInstitute of Cytology and Genetics; Novosibirsk state medical universityInstitute of Cytology and GeneticsInstitute of Cytology and GeneticsTomsk Research Institute of OncologyTomsk Research Institute of Oncology; National Research Tomsk State UniversityRoad clinical hospitalInstitute of Cytology and GeneticsBackground. Atrophic gastritis (AG), being the basic premalignant condition for the stomach cancer (SC), is commonly diagnosed and screened for by noninvasive biomarkers (pepsinogens, gastrin-17), however the data on those biomarkers at SC is inconsistent. Aim of investigation. To evaluate the markers of stomach atrophy along with risk factors of SC of different localization, histological type and stage in the «case series» study. Material and methods. Original investigation was designed as «case series», that included 85 patients with SC (48 m and 37 f, mean age 61.2±13,6 years) who were consistently referred to two medical institutions. All patients underwent interviewing the questionnaire concerning smoking and alcohol consumption, presence of gastroenterological symptoms and family history. Blood serum samples were analyzed using ELISA test kits «GastroPanel» («Biohit Plc», Finland). Manufacturer recommended threshold levels were used at diagnostics of AG. Results. The diagnosis of SC of the III to IV stage was established in 67.9% of patients. The most common location of the neoplasm was the stomach body (63,5%). Helicobacter pylori (H. pylori) infection was revealed by serological method in 74.1% of cases, of which in 15.1% the attempt of eradication treatment was carried out. In 90.6% of patients the adenocarcinoma of different differentiation grade was diagnosed, low degree of differentiation was the most common (57.6%). Signet-ring cell carcinoma was diagnosed in 7.1% of patients, undifferentiated tumor - in 2.4%. Pepsinogen-I (PGI) level under 50 mcg/l was found in 43.2% of patients, indicating different degrees of fundic atrophy. Significantly lower PGI scores were detected in SC patients with histologically verified atrophy. No significant differences in biomarker levels according to tumor location, histological type of SC and tumor stage were found. Conclusions. The «case series» study demonstrated high rate of late SC diagnostics with predominance of corpus location and the most malignant types. H. pylori infection was diagnosed in serologically in the most of patients, however attempts for eradication therapy was carried out only in 15% of patients. Fundic atrophy was diagnosed by serological tests in over 40% of patients, however no association with location, stage and morphological type of the tumor was established. Blood serum samples were analyzed using ELISA test kits «GastroPanel» («Biohit Plc», Finland). Manufacturer recommended threshold levels were used at diagnostics of AG.https://www.gastro-j.ru/jour/article/view/226рак желудкаатрофический гастритнеинвазивная диагностикапепсиногеныhelicobacter pylori
spellingShingle A. V. Belkovets
S. A. Kurilovich.
Yu. I. Ragino
L. V. Scherbakova
O. B. Cheremisina
N. V. Cherdyntseva
N. A. Andryushina
M. I. Voyevoda
Biomarkers of gastric atrophy at stomach cancer
Российский журнал гастроэнтерологии, гепатологии, колопроктологии
рак желудка
атрофический гастрит
неинвазивная диагностика
пепсиногены
helicobacter pylori
title Biomarkers of gastric atrophy at stomach cancer
title_full Biomarkers of gastric atrophy at stomach cancer
title_fullStr Biomarkers of gastric atrophy at stomach cancer
title_full_unstemmed Biomarkers of gastric atrophy at stomach cancer
title_short Biomarkers of gastric atrophy at stomach cancer
title_sort biomarkers of gastric atrophy at stomach cancer
topic рак желудка
атрофический гастрит
неинвазивная диагностика
пепсиногены
helicobacter pylori
url https://www.gastro-j.ru/jour/article/view/226
work_keys_str_mv AT avbelkovets biomarkersofgastricatrophyatstomachcancer
AT sakurilovich biomarkersofgastricatrophyatstomachcancer
AT yuiragino biomarkersofgastricatrophyatstomachcancer
AT lvscherbakova biomarkersofgastricatrophyatstomachcancer
AT obcheremisina biomarkersofgastricatrophyatstomachcancer
AT nvcherdyntseva biomarkersofgastricatrophyatstomachcancer
AT naandryushina biomarkersofgastricatrophyatstomachcancer
AT mivoyevoda biomarkersofgastricatrophyatstomachcancer